Roche (VTX:ROG) has been given a CHF 226 price objective by equities research analysts at Kepler Capital Markets in a report released on Wednesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Kepler Capital Markets’ target price indicates a potential downside of 3.07% from the stock’s current price.
Several other equities analysts have also issued reports on the company. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a “buy” rating in a research report on Thursday, September 21st. Jefferies Group set a CHF 290 target price on Roche and gave the stock a “buy” rating in a research report on Thursday, September 21st. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a research report on Monday, September 25th. BNP Paribas set a CHF 235 target price on Roche and gave the stock a “sell” rating in a research report on Monday, September 25th. Finally, Deutsche Bank set a CHF 258 target price on Roche and gave the stock a “neutral” rating in a research report on Wednesday, October 4th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of CHF 258.95.
Shares of Roche (VTX:ROG) traded down CHF 2.85 during trading hours on Wednesday, reaching CHF 233.15. The company’s stock had a trading volume of 2,450,000 shares, compared to its average volume of 1,570,000. The company has a market cap of $201,050.00 and a PE ratio of 20.72. Roche has a 12-month low of CHF 226.10 and a 12-month high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.